fbpx Skip to main content

WEDNESDAY, Feb. 17, 2021 (HealthDay News) — Overall pregnancy and live birth outcomes are similar for women with psoriasis and for the general population, according to a study published online Feb. 3 in JAMA Dermatology.

Alexa B. Kimball, M.D., M.P.H., from the Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, and colleagues reported pregnancy outcomes observed in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Data were included for 2,224 women of childbearing age (18 to 45 years).

The researchers identified 298 pregnancies among 220 women, with a general fertility rate of 18.9 per 1,000 women aged 18 to 45 years. Overall, 81.9 percent of the pregnancies resulted in birth, and 13.8 and 4.4 percent ended in spontaneous abortion and were electively terminated, respectively. Gestational age was available for 243 births: 90.9 percent were full term and 9.1 percent were born prematurely. Overall, there were 231 healthy newborns and 10, two, and one infants with a neonatal problem, a congenital anomaly, and stillbirth, respectively. Two hundred fifty-two of the 298 pregnancies were associated with biologic exposure before or during pregnancy. Women exposed to biologics had similar pregnancy outcomes as those exposed to nonbiologics. Of the women who became pregnant, at the time of enrollment into the registry, 33.8 percent had obesity and 55.0 percent were past or current smokers.

“Pregnancy outcomes among women with moderate-to-severe psoriasis in PSOLAR have remained consistent with previously reported data and the general population,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

You May Also Like::  ACA's Reach Surges With 200,000 New Signups, More States Involved

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More